Status | Study |
Recruiting |
Study Name: Laser Tissue Welding - Distal Pancreatectomy Sealing Study Condition: Pancreatic Tumor, Benign Pancreatic Neoplasms Pancreatic A Date: 2017-05-08 Interventions: Device: Distal Pancreatectomy Sealing Using LTW The device's intended use is to seal the pancreatic surf |
Not yet recruiting |
Study Name: Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Condition: Functional Pancreatic Neuroendocrine Tumor Malignant Somatostatinoma Date: 2016-07-10 Interventions: Drug: Capecitabine Given PO |
Terminated |
Study Name: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Condition: Estrogen Receptor-positive Breast Cancer Gastrinoma Date: 2014-10-22 Interventions: Drug: Everolimus Given PO Other Names: |
Recruiting |
Study Name: Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insuli Date: 2014-10-03 Interventions: Drug: regorafenib Given PO |
Withdrawn |
Study Name: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insuli Date: 2014-01-07 Interventions: Drug: dovitinib lactate Given |
Terminated |
Study Name: Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Condition: Gastrinoma Glucagonoma Insuli Date: 2014-01-07 Interventions: Drug: everolimus Given PO |
Active, not recruiting |
Study Name: Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insuli Date: 2013-04-02 Interventions: Drug: temozolomide Given PO |
Active, not recruiting |
Study Name: Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Condition: Gastrinoma Glucagonoma Insuli Date: 2012-01-10 Interventions: Drug: capecitabine Given PO |
Completed |
Study Name: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Condition: Gastrin-Producing Neuroendocrine Tumor Lung Carcinoid Tumor Date: 2010-09-16 Interventions: Biological: Cixutumumab Given |
Terminated |
Study Name: Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Condition: Pancreatic Cancer Date: 2010-01-25 Interventions: Drug: Bortezomib 1.3 mg/m^2 ad |